A better way to treat cancer, Brian Druker

Interviewee: Brian Druker. Brian Druker talks bout a better way to treat cancer.

But it always seemed to me that you were using very harsh chemicals to cure a disease and that was fantastic but it still seemed there had to be a better way and the better way was to understand what was driving the growth of these cancer cells and if we could get to that point maybe we could treat this disease more rationally. And I always figured wouldn't it be great just to be a part of that discovery that was likely to occur over the next 20 or 30 years.

cancer cells,harsh chemicals,cancer drug,gleevec,brian druker,discovery

Related Content

15082. Shutting down cancer with Gleevec, Brian Druker

Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.

  • ID: 15082
  • Source: DNAi

15057. Before and after Gleevec, Brian Druker

Brian Druker talks about the drug he developed as a turning point in the war on cancer.

  • ID: 15057
  • Source: DNAi

15054. Restoring hope with Gleevec, Brian Druker

Brian Druker talks about how Gleevec has restored patients' hope for the future.

  • ID: 15054
  • Source: DNAi

16109. Sense of urgency, Brian Druker

Brian Druker talks about sense of urgency.

  • ID: 16109
  • Source: DNAi

15056. Approval for Gleevec in record time, Brian Druker

Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.

  • ID: 15056
  • Source: DNAi

15055. Using DNA science to control CML, Brian Druker

Brian Druker talks about how the drug he designed targets the molecular cause of CML.

  • ID: 15055
  • Source: DNAi

15058. The first clinical success with Gleevec, Brian Druker

Brian Druker talks about Bud, the first patient restored to health by Gleevec™.

  • ID: 15058
  • Source: DNAi

1015. Diagnosis, Targeted therapies: Targeting activators, Sawyer 3

Professor Charles Sawyer explains that the CML clone makes mistakes in DNA replication and generates a diverse repertoire of mutations.

  • ID: 1015
  • Source: IC

15042. The first day of clinical trials for Gleevec, Bud and Yvonne

Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.

  • ID: 15042
  • Source: DNAi

1010. Diagnosis, Targeted therapies

Conventional cancer drugs are cellular poisons that block replication or some other aspect of cell growth. These drugs affect all cells – healthy or cancerous.

  • ID: 1010
  • Source: IC